US 11,834,462 B2
Somatostatin modulators and uses thereof
Sangdon Han, San Diego, CA (US); Sun Hee Kim, San Diego, CA (US); and Yunfei Zhu, San Diego, CA (US)
Assigned to CRINETICS PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Crinetics Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Apr. 6, 2022, as Appl. No. 17/714,825.
Application 17/714,825 is a continuation of application No. 17/511,326, filed on Oct. 26, 2021, abandoned.
Application 17/511,326 is a continuation of application No. 16/877,947, filed on May 19, 2020, granted, now 11,186,590, issued on Nov. 30, 2021.
Application 16/877,947 is a continuation of application No. 16/572,921, filed on Sep. 17, 2019, granted, now 10,696,689, issued on Jun. 30, 2020.
Claims priority of provisional application 62/732,735, filed on Sep. 18, 2018.
Prior Publication US 2023/0022513 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 211/06 (2006.01); C07D 401/14 (2006.01); A61K 9/08 (2006.01); C07D 498/04 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 9/06 (2006.01)
CPC C07D 498/04 (2013.01) [A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/4825 (2013.01); C07D 401/14 (2013.01)] 16 Claims
 
1. A method of suppressing secretion of growth hormone (GH), insulin, glucagon, insulin-like growth factor 1 (IGF-1), prolactin, or combinations thereof, in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound that has one of the following structures:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof.